Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXP800 in Advanced Cholangiocarcinoma
NCT06420349Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- May 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NXP800 in cholangiocarcinoma (CCA), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 12 months and Recommended Phase 2 Dose at 12 months. Started May 2024; status: terminated.
02
Drugs
NXP800
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06420349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420349.